Zhou X, Wang J, Zhang J, Copley-Merriman C, Torigoe Y, Reyes C, Seymour JF, Offner FC, Trneny M, Salles GA. Symptoms and toxicity of rituximab maintenance relative to observation following immunochemotherapy in patients with follicular lymphoma. Hematology. 2015 Apr;129(36). doi: 10.1179/1607845414Y.0000000179
Edwards T, Cadigan RJ, Evans JP, Henderson GE. Biobanks containing clinical specimens: defining characteristics, policies, and practices. Clin Biochem. 2014 Mar;47(4-5):245-51. doi: 10.1016/j.clinbiochem.2013.11.023
Candrilli SD, Manjunath R, Davis KL, Gidal BE. The association between antiepileptic drug and HMG-CoA reductase inhibitor co-medication and cholesterol management in patients with epilepsy. Epilepsy Res. 2010 Oct 1;91(2-3):260-6.
Earnshaw SR, Wilson M, Joshi AV. The effect of recombinant activated factor VII in the treatment of intracerebral hemorrhage on health plan budgets. Managed Care Interface. 2007 Jan 1;19(11):39-45.
Earnshaw SR, Wilson MR, Joshi AV. Health plan budget impact analysis of recombinant activated factor VII (rFVIIa) in the treatment of intracerebral hemorrhage. Managed Care Interface. 2006;19(11):39-45.
Earnshaw SR, Candrilli SD, Fernandes AW, Higashi MK. A cost-effectiveness analysis of antibiotic therapy in macrolide-resistant community-acquired pneumonia. Managed Care Interface. 2005 Oct 1;18(10):36-44.